Depakote for epilepsy, bipolar mania, and migraine prevention

Depakote is an anticonvulsant medicine containing divalproex sodium, used to treat manic episodes of bipolar disorder, various types of seizures including complex partial and absence seizures, and to prevent migraine headaches in adults. It is available as delayed-release tablets, extended-release tablets, and sprinkle capsules taken by mouth.

The medication acts to stabilize mood and reduce seizure activity but carries significant risks, including serious liver injury and fetal harm, so it requires careful monitoring and use with caution in specific populations.

Depakote is prescribed for the following:

• Manic episodes of bipolar disorder: Treatment of acute manic or mixed episodes, including patients with or without psychotic features.
• Epilepsy: Monotherapy and adjunctive therapy for complex partial seizures and simple and complex absence seizures in adults and pediatric patients aged 10 years and older. Also as adjunctive therapy in multiple seizure types that include absence seizures.
• Migraine prophylaxis: Prevention of migraine headaches in adults. Depakote is not effective for acute migraine treatment.

Treatment in pregnant women, especially for bipolar or epilepsy, is restricted due to risks to the fetus. For migraine prevention, it is contraindicated in pregnant women and women of childbearing potential not using effective contraception.

divalproex sodium

Depakote contains divalproex sodium, which adjusts the balance of neurotransmitters and electrical activity in the brain to help control seizures and mood. It works by increasing levels of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, which calms nerve activity related to seizures and mania. The precise mechanism for migraine prevention is not fully understood but may involve stabilization of nerve signals.

General instructions:

• All Depakote forms are oral. Delayed and extended-release tablets should be swallowed whole without crushing or chewing. Sprinkle capsules can be swallowed whole or sprinkled on soft food and swallowed immediately without chewing.
• Patients should take Depakote daily as prescribed. If a dose is missed, take it as soon as possible unless near the next scheduled dose. Do not double doses.

Manic episodes:

• Delayed-release tablets: Start at 750 mg daily, divided doses, increase rapidly to therapeutic effect. Max 60 mg/kg/day.
• Extended-release tablets: Start at 25 mg/kg/day once daily, increase rapidly to therapeutic effect. Max 60 mg/kg/day.

Complex partial seizures (adults and children ≥10 years):

• Start at 10-15 mg/kg/day, increase weekly by 5-10 mg/kg/day to clinical response, generally below 60 mg/kg/day.
• Check plasma levels if response is unsatisfactory. Plasma concentration target range: 50-100 mcg/mL.
• Conversion to monotherapy involves gradual withdrawal of prior AEDs with monitoring.
• Doses above 60 mg/kg/day not established as safe.

Absence seizures:

• Initial dose 15 mg/kg/day, increase by 5-10 mg/kg/day weekly to seizure control or limiting side effects. Max 60 mg/kg/day.
• Therapeutic serum levels generally 50-100 mcg/mL, but may vary.

Migraine prophylaxis (adults):

• Delayed-release tablets: 250 mg twice daily starting dose, increasing up to 1000 mg/day as needed.
• Extended-release tablets: Begin 500 mg once daily for 1 week, then increase to 1000 mg once daily.

Elderly patients:

• Start at lower doses and increase slowly with monitoring due to decreased clearance and increased sensitivity.

• Patients with hepatic disease or significant hepatic dysfunction.
• Known mitochondrial disorders caused by POLG mutations (e.g., Alpers-Huttenlocher Syndrome) and children under two years suspected of having a POLG-related disorder.
• Known hypersensitivity to divalproex sodium, sodium valproate, or valproic acid (including multiorgan hypersensitivity, serious dermatologic reactions, angioedema).
• Patients with known urea cycle disorders.
• For migraine prophylaxis: pregnant women and women of childbearing potential not using effective contraception.

Serious risks and precautions:

• Hepatotoxicity: Fatal liver failure can occur, especially in children under 2 years, patients with mitochondrial POLG mutations, or those with prior liver disease. Monitor liver function tests before and during treatment, particularly the first 6 months. Symptoms like malaise, weakness, lethargy, facial swelling, anorexia, and vomiting require urgent evaluation.
• Fetal risk: Valproate causes major birth defects including neural tube defects, decreased IQ, and neurodevelopmental disorders. Contraindicated in pregnancy for migraine prophylaxis and discouraged in women of childbearing potential unless no alternatives exist with use of effective contraception.
• Pancreatitis: Cases of potentially fatal pancreatitis, sometimes hemorrhagic, have been reported at any time during treatment. Patients should be warned about symptoms such as abdominal pain, nausea, vomiting, or anorexia. Valproate should be discontinued if pancreatitis is diagnosed.
• Suicidal behavior: Antiepileptic drugs, including Depakote, increase risk of suicidal thoughts or behavior. Monitor patients for depression, suicidal ideation, or behavioral changes.
• Hematologic effects: Thrombocytopenia risk increases with higher plasma levels. Regular monitoring of platelet counts and coagulation tests advised.
• Hyperammonemia and encephalopathy: May occur especially with concurrent topiramate use. Measure ammonia if unexplained lethargy, vomiting, or mental status changes develop; consider stopping valproate.
• Drug hypersensitivity: Serious dermatologic reactions including DRESS, angioedema require immediate discontinuation unless ruled out.
• Urea cycle disorders: Contraindicated due to risk of fatal hyperammonemic encephalopathy. Evaluate patients with suggestive histories before use.
• Hypothermia: Rarely reported during therapy, sometimes with hyperammonemia, especially with topiramate.

Common side effects:

• Gastrointestinal upset (nausea, vomiting, abdominal pain)
• Somnolence or sedation, especially in elderly
• Weight gain
• Tremor
• Hair loss
• Thrombocytopenia (low platelet counts), especially at higher doses
• Elevated liver enzymes

Serious adverse reactions:

• Hepatotoxicity and liver failure
• Pancreatitis, potentially fatal
• Multiorgan hypersensitivity reactions (DRESS)
• Severe dermatologic reactions including angioedema
• Hyperammonemic encephalopathy

• Valproate levels may be affected by and can affect plasma concentrations of clonazepam, diazepam, ethosuximide, lamotrigine, tolbutamide, phenobarbital, carbamazepine, and phenytoin. Periodic monitoring of concomitant antiepileptic drug levels is recommended.
• Caution when coadministered with topiramate due to increased risk of hyperammonemia, encephalopathy, and hypothermia.
• Dosage adjustment of concomitant antiepileptics may be required during initiation and titration of Depakote.

Pregnancy:

Valproate causes major congenital malformations, including neural tube defects, craniofacial, cardiovascular, limb malformations, and significantly decreased IQ and neurodevelopmental disorders. It is contraindicated for migraine prophylaxis in pregnancy and should not be used in pregnant women with epilepsy or bipolar disorder unless no adequate alternatives exist. Women of childbearing potential must use effective contraception and be counseled on risks.

Lactation:

Information not provided in supplied evidence.